||Registry of biomedical companies:
   [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Z] 540 active entries
106 Jiangdongzhong Road, suite B 1306
OGpharma is a professional service provider for the pharmaceutical industry providing pharmacology, biology, DMPK, and toxicology testing services. OGpharma's mission is to provide the highest quality R&D services while helping our customers advancing their projects in a timely and cost effective manner.
Ogpharma has provided services and collaborated with over 80 companies around the world. Our current clients include small and large pharmaceutical companies in North America, Europe and Japan, and China. We pledge to serve our clients with the highest level of quality, efficiency, passion, and commitment. Through our efforts, OGpharma has grown into one of the top drug discovery service companies in China.
- In Vivo and in vitro Pharmacology: OGpharma in vivo and in vitro pharmacology services include oncology, inflammation diseases, metabolic diseases, CNS, pain and other established animal models and procedures. Our large collections of human tumor xenograft models, human tumor tissue bank allow partners to select and identify relevant tumor models for compounds evaluation and help accelerate their drug discovery and development process.
- Biology: OGpharma biology provides a broad spectrum of high quality services to support various stages of drug discovery and development. With strong training in biochemistry, molecular and cellular biology, our teams are highly experienced, and focused on customer assay development, compound evaluation using various cell culture models.
- PK / Bioanalytical: OGpharma offers comprehensive in vivo and in vitro pharmacokinetic (PK), toxicokinetics, bioanalytical and discovery bioanalytical services to our partners.
- Preclinical toxicity Services (PTS): OGpharma's toxicology facility enables us to evaluate toxicity of the drug candidates by using mice, rats, dogs, monkeys, etc.
Last update of this entry: July 11, 2017